SCHEMBL18026087

SCHEMBL18026087

CC(O)C1OC(n2cnc3c(N)ccnc32)C(O)C1O

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 3/20 0.58
▸ ADORA2A P29274 2/20 0.58
▸ DNMT1 P26358 1/20 0.52
▸ DNMT3B Q9UBC3 1/20 0.52
▸ PRMT5 O14744 4/20 0.48
▸ WDR77 Q9BQA1 4/20 0.48
▸ AHCY P23526 3/20 0.46
▸ ADORA3 P0DMS8 2/20 0.43
▸ DOT1L Q8TEK3 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSP90AA1 P07900 1/20 0.43
▸ HSP90B1 P14625 1/20 0.43
▸ ADORA1 P30542 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18026021 1.00 ADORA2B (0.58) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026026 1.00 ADORA2B (0.58) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026007 0.88 ADORA2A (0.56) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026012 0.88 ADORA2A (0.56) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026081 0.88 ADORA2A (0.56) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026074 0.87 ADORA2A (0.60) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026050 0.87 ADORA2A (0.60) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026027 0.87 ADORA2A (0.60) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026006 0.85 ADORA2A (0.58) ADORA2BADORA2ADNMT1DNMT3BPRMT5
SCHEMBL18026013 0.85 ADORA2A (0.58) ADORA2BADORA2ADNMT1DNMT3BPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2016-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244475-A1 SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS TYMP, NME1, PNP ADORA2B 1363/4885ADORA2A 631/4885DNMT1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback